Patrick O'Neil to Anti-Obesity Agents
This is a "connection" page, showing publications Patrick O'Neil has written about Anti-Obesity Agents.
Connection Strength
1.274
-
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 11; 19(11):1529-1536.
Score: 0.566
-
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016 11; 24(11):2278-2288.
Score: 0.135
-
The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond). 2016 09; 40(9):1369-75.
Score: 0.131
-
Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring). 2014 Oct; 22(10):2137-46.
Score: 0.115
-
Pharmacotherapy of obesity: clinical treatments and considerations. Am J Med Sci. 2013 Apr; 345(4):284-288.
Score: 0.105
-
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012 Jul; 20(7):1426-36.
Score: 0.098
-
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
Score: 0.046
-
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999 Jun; 69(6):1108-16.
Score: 0.040
-
Clinical trial design for obesity agents: a workshop report. Obes Res. 1998 Jul; 6(4):311-5.
Score: 0.038